{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:12:05Z","timestamp":1790860325234,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>DNA-damage-inducible transcript 3 (<jats:italic>DDIT3<\/jats:italic>), a candidate tumor suppressor gene (TSG), has been found involved in the regulation of cellular growth and differentiation. The epigenetic changes of TSGs are recently recognized as an abnormal mechanism contributing to the development of chronic myeloid leukemia (CML). The aim of this study was to investigate the methylation status of <jats:italic>DDIT3<\/jats:italic> gene in CML patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The methylation status of <jats:italic>DDIT3<\/jats:italic> promoter was detected in the bone marrow mononuclear cells from 53 patients with CML using methylation-specific PCR (MSP). The expression levels of <jats:italic>DDIT3<\/jats:italic> and <jats:italic>bcr\/abl<\/jats:italic> transcript were determined by real-time quantitative PCR (RQ-PCR). Clinical data of these patients were collected and analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The aberrant methylation of <jats:italic>DDIT3<\/jats:italic> gene promoter was found in 35 of 53 (66%) CML cases. Correlation was not found between <jats:italic>DDIT3<\/jats:italic> promoter hypermethylation and the age, sex, hemoglobin concentration, platelet counts, chromosomal abnormalities, <jats:italic>bcr\/abl<\/jats:italic> transcript, and staging of CML patients (<jats:italic>P<\/jats:italic> &gt; 0.05), but found between <jats:italic>DDIT3<\/jats:italic> promoter hypermethylation and WBC counts of CML cases (R = 0.781, <jats:italic>P<\/jats:italic> &lt; 0.001). The level of <jats:italic>DDIT3<\/jats:italic> transcript in CML patients was significantly lower than that in controls (median 3.28 vs 19.69, <jats:italic>P<\/jats:italic> &lt; 0.001), however, there was no difference in the level of <jats:italic>DDIT3<\/jats:italic> transcript between methylation-positive CML cases (0.05-65.32, median 2.13) and methylation- negative CML cases (0.12-126.04, median 3.92) (<jats:italic>P<\/jats:italic> &gt; 0.05).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our results demonstrate that aberrant methylation of <jats:italic>DDIT3<\/jats:italic> occurs in CML frequently.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1756-9966-29-54","type":"journal-article","created":{"date-parts":[[2010,5,25]],"date-time":"2010-05-25T06:14:07Z","timestamp":1274768047000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Methylation status of DDIT3 gene in Chronic Myeloid Leukemia"],"prefix":"10.1186","volume":"29","author":[{"given":"Ya-li","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-ming","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-hui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,5,23]]},"reference":[{"key":"301_CR1","doi-asserted-by":"publisher","first-page":"973","DOI":"10.4065\/81.7.973","volume":"81","author":"A Quint\u00e1s-Cardama","year":"2006","unstructured":"Quint\u00e1s-Cardama A, Cortes JE: Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc. 2006, 81: 973-988. 10.4065\/81.7.973.","journal-title":"Mayo Clin Proc"},{"key":"301_CR2","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/nrc2147","volume":"7","author":"JV Melo","year":"2007","unstructured":"Melo JV, Barnes DJ: Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007, 7: 441-453. 10.1038\/nrc2147.","journal-title":"Nat Rev Cancer"},{"key":"301_CR3","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","volume":"103","author":"B Calabretta","year":"2004","unstructured":"Calabretta B, Perrotti D: The biology of CML blast crisis. Blood. 2004, 103: 4010-4022. 10.1182\/blood-2003-12-4111.","journal-title":"Blood"},{"key":"301_CR4","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/S0168-9525(99)01971-X","volume":"16","author":"SB Baylin","year":"2000","unstructured":"Baylin SB, Herman JG: DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 2000, 16: 168-174. 10.1016\/S0168-9525(99)01971-X.","journal-title":"Trends Genet"},{"key":"301_CR5","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1146\/annurev.pharmtox.45.120403.095832","volume":"45","author":"M Esteller","year":"2005","unstructured":"Esteller M: Aberrant DNA methylation as a cancer-inducing mechanism. Annu Rev Pharmacol Toxicol. 2005, 45: 629-656. 10.1146\/annurev.pharmtox.45.120403.095832.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"301_CR6","first-page":"973","volume":"56","author":"JP Issa","year":"1996","unstructured":"Issa JP, Zehnbauer BA, Civin CI, Collector MI, Sharkis SJ, Davidson NE, Kaufmann SH, Baylin SB: The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. Cancer Res. 1996, 56: 973-977.","journal-title":"Cancer Res"},{"key":"301_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1600-0609.2008.01178.x","volume":"82","author":"J Qian","year":"2009","unstructured":"Qian J, Wang YL, Lin J, Yao DM, Xu WR, Wu CY: Aberrant methylation of the death-associated protein kinase 1 (DAPK1) CpG inland in chronic myeloid leukemia. Eur J Haematol. 2009, 82: 119-123. 10.1111\/j.1600-0609.2008.01178.x.","journal-title":"Eur J Haematol"},{"key":"301_CR8","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1182\/blood.V95.10.3208","volume":"95","author":"JR Melki","year":"2000","unstructured":"Melki JR, Vincent PC, Brown RD, Clark SJ: Hypermethyation of E-cadherin in leukemia. Blood. 2000, 95: 3208-3213.","journal-title":"Blood"},{"key":"301_CR9","first-page":"837","volume":"57","author":"JG Herman","year":"1997","unstructured":"Herman JG, Civin CI, Issa JP, Collector MI, Skarkis SJ, Baylin SB: Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res. 1997, 57: 837-841.","journal-title":"Cancer Res"},{"key":"301_CR10","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1046\/j.1523-1747.1998.00123.x","volume":"110","author":"EV Maytin","year":"1998","unstructured":"Maytin EV, Habener JF: Transcription factors C\/EBP alpha, C\/EBP beta, and CHOP (Gadd153) expressed during the differentiation program of keratinocytes in vitro and in vivo. J Invest Dermatol. 1998, 110: 238-246. 10.1046\/j.1523-1747.1998.00123.x.","journal-title":"J Invest Dermatol"},{"key":"301_CR11","doi-asserted-by":"publisher","first-page":"12446","DOI":"10.1073\/pnas.220425597","volume":"97","author":"QQ Tang","year":"2000","unstructured":"Tang QQ, Lane MD: Role of C\/EBP homologous protein (CHOP-10) in the programmed activation of CCAAT\/enhancer-binding protein-beta during adipogenesis. Proc Natl Acad Sci USA. 2000, 97: 12446-12450. 10.1073\/pnas.220425597.","journal-title":"Proc Natl Acad Sci USA"},{"key":"301_CR12","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1210\/en.2003-0868","volume":"145","author":"RC Pereira","year":"2004","unstructured":"Pereira RC, Delany AM, Canalis E: CCAAT\/enhancer binding protein homologous protein (DDIT3) induces osteoblastic cell differentiation. Endocrinology. 2004, 145: 1952-1960. 10.1210\/en.2003-0868.","journal-title":"Endocrinology"},{"key":"301_CR13","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1182\/blood.V93.10.3369.410k11_3369_3378","volume":"93","author":"M Coutts","year":"1999","unstructured":"Coutts M, Cui K, Davis KL, Keutzer JC, Sytkowski AJ: Regulated expression and functional role of the transcription factor CHOP (GADD153) in erythroid growth and differentiation. Blood. 1999, 93: 3369-3378.","journal-title":"Blood"},{"key":"301_CR14","first-page":"3250","volume":"56","author":"AD Friedman","year":"1996","unstructured":"Friedman AD: GADD153\/CHOP, a DNA damage-inducible protein, reduced CAAT\/enhancer binding protein activities and increased apoptosis in 32D c13 myeloid cells. Cancer Res. 1996, 56: 3250-3256.","journal-title":"Cancer Res"},{"key":"301_CR15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/0014-5793(96)01016-2","volume":"395","author":"M Matsumoto","year":"1996","unstructured":"Matsumoto M, Minami M, Takeda K, Sakao Y, Akira S: Ectopic expression of CHOP (GADD153) induces apoptosis in M1 myeloblastic leukemia cells. FEBS Lett. 1996, 395: 143-147. 10.1016\/0014-5793(96)01016-2.","journal-title":"FEBS Lett"},{"key":"301_CR16","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.leukres.2005.05.020","volume":"29","author":"J Qian","year":"2005","unstructured":"Qian J, Chen Z, Lin J, Wang W, Cen J: Decreased expression of CCAAT\/enhancer binding protein zeta (C\/EBPzeta) in patients with different myeloid diseases. Leuk Res. 2005, 29: 1435-1441. 10.1016\/j.leukres.2005.05.020.","journal-title":"Leuk Res"},{"key":"301_CR17","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1182\/blood-2006-08-040147","volume":"109","author":"S Agrawal","year":"2007","unstructured":"Agrawal S, Hofmann WK, Tidow N, Ehrich M, Boom van den D, Koschmieder S, Berdel WE, Serve H, M\u00fcller-Tidow C: The C\/EBP\u03b4 tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. Blood. 2007, 109: 3895-3905. 10.1182\/blood-2006-08-040147.","journal-title":"Blood"},{"key":"301_CR18","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1158\/0008-5472.CAN-08-0483","volume":"68","author":"B Hackanson","year":"2008","unstructured":"Hackanson B, Bennett KL, Brena RM, Jiang J, Claus R, Chen SS, Blagitko-Dorfs N, Maharry K, Whitman SP, Schmittgen TD, L\u00fcbbert M, Marcucci G, Bloomfield CD, Plass C: Epigenetic modification of CCAAT\/enhancer binding protein A expression in acute myeloid leukemia. Cancer Res. 2008, 68: 3142-3151. 10.1158\/0008-5472.CAN-08-0483.","journal-title":"Cancer Res"},{"key":"301_CR19","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.leukres.2008.07.027","volume":"33","author":"E Jost","year":"2009","unstructured":"Jost E, do ON, Wilop S, Herman JG, Osieka R, Galm O: Aberrant DNA methylation of the transcription factor C\/EBP\u03b1 in acute myelogenous leukemia. Leuk Res. 2009, 33: 443-449. 10.1016\/j.leukres.2008.07.027.","journal-title":"Leuk Res"},{"key":"301_CR20","doi-asserted-by":"publisher","first-page":"9821","DOI":"10.1073\/pnas.93.18.9821","volume":"93","author":"JG Herman","year":"1996","unstructured":"Herman JG, Graff JR, My\u00f6h\u00e4nen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996, 93: 9821-9826. 10.1073\/pnas.93.18.9821.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-9966-29-54.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T04:44:08Z","timestamp":1630471448000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/1756-9966-29-54"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,23]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["301"],"URL":"https:\/\/doi.org\/10.1186\/1756-9966-29-54","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,23]]},"assertion":[{"value":"7 April 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"54"}}